"Chemotherapy kills, and cancer patients die from chemotherapy, not the cancer itself!”
Chemotherapy is jointly manufactured by doctors and pharmaceutical companies**, chemotherapy is useless!”
Since the development of ** to the present day, there are many different versions of this cancer chemotherapy: it has been mentioned that "50% of cancer patients die from chemotherapy drugs (within 30 days of the start of chemotherapy), not the cancer itself." "I even took out the September 2016 journal of The Lancet Oncology ** as evidence, but in fact, when I opened it, it was simply out of nowhere.
The original journal data read: Of the 29,112 breast cancers, 700 died within 30 days of the start of chemotherapy, the mortality rate was 24%【1】。50% of cancer patients die from chemotherapy, chemotherapy is uselessWhen will this distorted data stop here?
Is chemotherapy useful?How big is the effect?
Chemotherapy is toxic, but its benefits far outweigh its damage. From 1975 to 2009, the 5-year survival rate of childhood cancer in the United States showed that the 5-year survival rate of leukemia increased from 48% to 84% [2].
In 2011, scientists counted 100,000 female breast cancer patients with controlled data, showing that chemotherapy reduced the 10-year mortality rate by an average of one-third compared with no chemotherapy [3].
Doctor's advice: cancer chemotherapy patients should focus on how to reduce the toxicity and side effects of chemotherapy and reduce the sequelae
As one of the mainstream methods of cancer, the role of chemotherapy is undeniable, and patients should pay more attention to the question of how to receive chemotherapyReduce the toxicity and side effects of chemotherapy, reduce sequelae, and improve the quality of life
Compared with: white needles, blood-generating agents, antiemetics. For these interventions that treat the symptoms but not the root cause, cancer chemotherapy patients should use adjuvant drugs that can activate and protect normal cells in nature and have no primary treatment. From the immunoadjuvant products commonly used in cancer chemotherapy patients at present,4 generationsRare monomeric ginsenoside rh2 enhances the S-typeMore acceptable to patients.
According to relevant studies,4 generationsRare monomeric ginsenoside rh2 enhances the S-typeThis active small molecule has a good effect on alleviating the side effects of chemotherapy, stabilizing the immune system and improving the efficacy in the process of combined chemoradiotherapy**.
In the clinical study data of "Efficacy of Ginsenoside RH2 Combined with Cisplatin + Pemetrexed Chemotherapy** for Advanced Lung Cancer", it was pointed out that after chemotherapy, the total effective rate of oral monomeric ginsenoside RH2 combined with chemotherapy drugs** was 4906%, which is 24% more effective than chemotherapy alone**53%, doubling its effectiveness [4].
In addition, the data showed that the immune function of patients with monomeric ginsenoside rh2 combined with chemotherapy drugs was more stable than that of patients with chemotherapy alone [4].
Let's look at another clinical study data on "Clinical Observation of Ginsenoside RH2 Combined with Concurrent Radiotherapy and Chemoradiotherapy for Advanced Cervical Cancer": The investigators randomly divided 68 patients with advanced cervical cancer into 34 study groups and 34 control groups for comparative observation, and the results showed that the chemotherapy adverse reactions (including gastrointestinal and bone marrow suppression) in the monomeric ginsenoside RH2 combined with chemotherapy research group were much smaller than those in the control group with chemotherapy alone [5].
It is not difficult to see the actual utility of monomeric ginsenoside rh2-enhanced S-type small molecule in combination with chemotherapy** tumor patients from the above clinical research data. As for whether the monomeric ginsenoside RH2 can be used for a long time, safety and other issues, Harbin Medical University, Zhejiang Provincial Center for Disease Control and Prevention, National Doping and Sports Nutrition Testing and Research Center and other authoritative institutions have also given answers, in the corresponding toxicology test, stability test and relevant national standard test on ginsenoside RH2, the results show that the monomeric ginsenoside RH2 is non-toxic and can be taken for a long time [6].
4 generationsRare monomeric ginsenoside rh2 enhances the S-typeThe reason why it is favored in the tumor group is also because it contains extremely high content, there are no other impurities, and it has been filed by the State Food and Drug Administration. It can be said that among the many chemotherapy adjuvant immune products, it is very rare, and its sales volume in major e-commerce has always ranked among the top few, which also fully proves this.
There is no doubt about the role of chemotherapy in fighting tumors, and how to improve its efficacy, help patients reduce side effects, improve quality of life, and reduce sequelae on this basis is the focus of modern anti-cancer medical research. Now, with the research and development of chemotherapy drugs and the emergence of related adjuvant immune products, it is believed that chemotherapy will have a higher effect on cancer.
1、michael willington and others. 30-daymortality after systemic anticancer treatment for breast and lung cancer in england: a population-based, observational study. volume 17, no. 9, p1203-1216, sept 2016.
3, Han Yaofeng, Wang Qiqi, Fang Ya. Temporal distribution of breast cancer risk in women after surgery. China Health Statistics. Vol. 28, No. 6: 661-664
4. "Efficacy of ginsenoside RH2 combined with cisplatin + pemetrexed chemotherapy ** for advanced lung cancer" Zhao Mingyan, Hu Shubo, Chu Xu, Qiu Yuzhen.
5. Clinical observation of ginsenoside rh2 combined with concurrent chemoradiotherapy for advanced cervical cancer, Oncology Pharmac, 2013, 3(04): 286-289Hunan Xiangtan Maternal and Child Health Hospital.
6. Tao Lihua, Wei Jianhua, Pan Xiaopeng, Dong Li, Yu Limei, Gao Feng, Zhang Dazheng, Yu Shulian, Ginsenoside Rh2 Toxicology Experiment;